Among other potential applications, this epigenetic marker can be used for predicting the development of neurodegenerative diseases, as alterations in the ELOVL2 methylation status have been observed in patients at early stages of Alzheimer’s disease [35]. This evidence concerns the gene ELOVL2 and Alzheimer disease.